U.S. stock night market volatility: HeartBeam rose 7.38% in the night market, with active capital flow, raising volatility concerns in the sector?

U.S. Stock Night Market Movements HeartBeam rose 7.38% in the night market. There have been no significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news Stocks with High Trading Volume in the Industry ResMed rose 0.34% in the night market. Based on recent key news: On December 16, Baird lowered ResMed's target price from $300 to $275, putting pressure on the stock price. Analysts pointed out that the potential for revenue and earnings per share growth is unclear, and competition from Philips is intensifying. On December 17, analyst Rescott downgraded ResMed's rating from outperform to neutral and lowered the target price to $275, further affecting market confidence. On December 19, ResMed announced it would participate in the J.P. Morgan Healthcare Conference on January 12, 2026, which may impact future market performance. The competition in the healthcare industry is intensifying, and policy changes need to be monitored. TransMedics rose 1.18% in the night market. Based on recent news: On December 18, Canaccord Genuity raised TransMedics' target price from $147 to $148. This move indicates analysts' optimistic outlook on the company's prospects, driving the stock price up. On December 18, although TransMedics was rated as "moderate buy," top analysts believe there are five stocks that are more worthy of investment. This news may have some impact on investor confidence, but the overall effect is limited. Analysts maintain an optimistic outlook on the company's prospects. Zimmer Biomet fell 0.27% in the night market. Based on recent key news: On December 16, Zimmer Biomet partnered with OneStep to integrate advanced gait and mobility analysis technology into its care management platform. This collaboration aims to enhance post-operative recovery monitoring capabilities, pushing the stock price up by 0.92%. Source: RTTNews On December 16, Baird lowered Zimmer Biomet's target stock price from $117 to $100, leading to increased market concerns about its future performance. Source: Baird On December 17, Zimmer Biomet announced a quarterly cash dividend of $0.24 per share, and the dividend payment plan may have a stabilizing effect on the stock price. Source: Reuters The trend of technology integration in the healthcare industry is significant, and capital inflows are stable